Status and phase
Conditions
Treatments
About
This is a single-arm phase II trial of Pembrolizumab (Keytruda) in patients with advanced, unresectable hepatocellular carcinoma. The primary objective is to assess its therapeutic efficacy in patients with unresectable hepatocellular carcinoma (HCC).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Patients must have diagnosis of advanced hepatocellular cancer (HCC) by one of the following:
Measurable disease as defined by RECIST v1.1 (provided in Section 14.0).
Radiographic progression on previously treated areas (as defined by RECIST v1.1).
Subject refusal for sorafenib treatment or intolerance to sorafenib are also allowed (intolerance is defined as ≥ 28 days of sorafenib (not necessarily consecutive) or ≥grade 3 toxicity due to sorafenib which does not resolve with appropriate supportive care).
Patients should have failed at least one prior systemic therapy regimen which could include sorafenib. Patients may have progressed on sorafenib, been intolerant of, or refused sorafenib. Patients who are documented to refuse systemic chemotherapy or sorafenib are also eligible. No limit to prior systemic therapy. Prior locoregional therapy such as surgery, radiofrequency ablation or transarterial chemoembolization are also allowed, provided that progression has been documented after these therapies, and ≥4 weeks have elapsed since the last therapy; (these will not be counted as systemic therapy).
Child-Pugh Classification with score ≤ 7 points. See Appendix G for criteria.
Age ≥ 18 years
Estimated life expectancy, in the judgement of the Investigator, of at least ≥ 12 weeks.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. See Appendix C.
Adequate bone marrow function as defined below:
Adequate liver function as defined below:
Adequate coagulation as defined by:
Adequate renal function as defined by one of the following:
Suitable venous access to allow for all study-related blood sampling.
Female subject of childbearing potential (CBP) must have a negative urine or serum pregnancy within 3 days prior to receiving the first dose of study medication.
Females of child bearing potential that are sexually active must agree to either practice 2 medically accepted highly effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 120 days after the last dose of study drug. See Appendix H for protocol-approved highly effective methods of contraceptive combinations. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
Negative test for pregnancy is required of females of child-bearing potential; A female of child bearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria:
Conception while on treatment must be avoided
Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Ability to understand and willingness to sign a written informed consent document.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
29 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal